Disruption of mitochondrial transport, distribution and dynamics arises early in the progression of multiple neu- rodegenerative disorders caused by environmental and genetic factors, and could be a causative factor in neu- ronal failure. However, the molecular mechanisms of mitochondrial trafficking inhibition and biomarkers of early mitochondrial dysfunction are undefined. Lack of such knowledge limits development of tools for early diagno- sis, monitoring disease progression, and design of efficient therapeutic strategies for neurodegenerative disor- ders. The objective in this application is using advance technologies to develop an integral panel of mitochon- drial/metabolomic biomarkers for early diagnosis of mitochondrial dysfunction in neurodegenerative disorders caused by genetic and environmental factors and to determine molecular mechanism of mitochondrial traffick- ing inhibition that could be common for multiple diseases. The central hypothesis is that genetic and environ- mental stressors initiate mitochondrial dysfunction through the common mechanism that involves disruption of mitochondrial dynamics that reflects on and could be detected early by analyzing dynamic alterations in me- tabolomic signatures and metabolic networks. The rationale for the proposed research is that establishment of mitochondrial and metabolomic signatures as a panel of candidate biomarkers will allow validation in a larger cohort of patients whether these biomarkers could be used for early diagnosis and prediction/monitoring of dis- ease progression. Guided by strong preliminary data, this hypothesis will be tested by pursuing four specific aims: 1) Establish a correlation algorithm between altered parameters of mitochondrial dynamics and signature metabolomic biomarkers in development of mitochondrial dysfunction in neurodegeneration, 2) Validate the use of integral biomarkers of early mitochondrial dysfunction for monitoring the disease progression in trans- genic animal models for AD, HD and PD, and environmental toxicity in vivo, 3) Determine the molecular mechanism of mitochondrial trafficking inhibition induced by environmental and genetic stressors, and 4) Es- tablish the relationship between integral mitochondrial biomarkers and progression of disease in AD, HD and PD patients. We will apply advanced biochemical and cell biology techniques combined with utilization of the analytical metabolomic platforms based on 18O-assisted GC/MS, LC/MS/MS, 1H NMR and 18O-assisted 31P NMR technologies to establish the relationship between altered mitochondrial dynamics and metabolomic pro- files and global changes in energetic and metabolic signaling circuits in neurons, tissue and body fluids from transgenic animal models and human patients that are associated with Mito dysfunction caused by genetic and environmental stressors.
The proposed research is relevant to the FOA purpose because it aims to understand the mechanism of how multiple genetic and environmental stressors affect mitochondrial dynamics and metabolomic profile leading to mitochondrial dysfunction and neurodegeneration. The objectives of this study is to develop an integral panel of mitochondrial/metabolomic biomarkers for early detection of mitochondrial dysfunction caused by genetic and environmental stressors using advance imaging and metabolomic technologies in disease-relevant trans- genic animal models, neuronal cells and human tissues/body fluids specific to the particular disease. We will dissect the significance of a novel molecular mechanism of toxin-induced trafficking inhibition that leads to mi- tochondrial dysfunction and validate whether a panel of biomarkers identified in the study could be used to monitor the extent of neurodegeneration. The successful outcomes of research will be validated in larger co- hort of patients to determine whether changes in mitochondrial dynamics and metabolomic signature could be used for early diagnosis and prediction/monitoring the disease progression.
|Trushina, Eugenia; Canaria, Christie A; Lee, Do-Yup et al. (2014) Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo. Hum Mol Genet 23:129-44|
|Trushina, Eugenia; Mielke, Michelle M (2014) Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta 1842:1232-9|
|Snyder, Heather M; Carrillo, Maria C; Grodstein, Francine et al. (2014) Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10:109-14|
|Trushina, Eugenia; Dutta, Tumpa; Persson, Xuan-Mai T et al. (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 8:e63644|
|Trushina, Eugenia; Nemutlu, Emirhan; Zhang, Song et al. (2012) Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 7:e32737|